Chinese pharmaceutical company Harbin Gloria Pharmaceuticals intends to issue medium-term notes due 2019 in a public offering to raise CNY1.6bn ($243.13m).

F. Hoffmann-La Roche (Roche) and Warp Drive Bio have formed a partnership to deploy the latter’s genome mining platform to develop antibiotics for bacterial infections.

Warp Drive Bio will receive an upfront payment of $87m and up to $300m in milestone payments for sales on products licensed to Roche

Roche is a Switzerland-based pharmaceutical company, while Warp Drive Bio is a drug discovery company based in the US.

F. Hoffmann-La Roche (Roche) and Warp Drive Bio have formed a partnership to deploy the latter’s genome mining platform to develop antibiotics for bacterial infections.”

US-based biotechnology company Intrexon plans to raise $100m through the private placement of one million series A redeemable preferred stock priced at $100 a share.

Opiant Pharmaceuticals plans to raise $150m through a public offering of common stock and warrants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US-based pharmaceutical company plans to use the funds for general corporate purposes.

Lipocine plans to issue shares of its common stock in a public offering to raise $25m.

The US-based pharmaceutical firm plans to use the funds towards general corporate purposes.